Status:
COMPLETED
An Open-Label, Dose-Escalation Study of AZD2461
Lead Sponsor:
AstraZeneca
Conditions:
Refractory Solid Tumors
Cancer Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461. This is th...
Eligibility Criteria
Inclusion
- Patients with confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy.
- Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1
- Patients must be 18 years of age
- Using adequate contraceptive measures, be surgically sterile or post-menopausal
- Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. If tissue is not available, a patient will still be eligible for enrollment into the study..
Exclusion
- Patients currently receiving cancer therapy
- Use of investigation anti-cancer drug or major surgery, radiotherapy or immunotherapy with the last 21 days
- cardiac disease
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01247168
Start Date
November 1 2010
End Date
May 1 2011
Last Update
June 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nashville, Tennessee, United States